Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - The International Lanreotide and Interferon Alfa Study Group

Journal of Clinical Oncology

Volumn 21, Issue 14, 2003, Pages 2689-2696

  Faiss, Siegbert ^b   Pape, Ulrich Frank ^b   Böhmig, Michael ^b   Dörffel, Yvonne ^b   Mansmann, Ulrich ^b   Golder, Werner ^b   Riecken, Ernst Otto ^b   Wiedenmann, Bertram ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; SOMATOSTATIN DERIVATIVE; ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; CYCLOPEPTIDE; DRUG DERIVATIVE; SOMATOSTATIN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG WITHDRAWAL; FOLLOW UP; GASTROINTESTINAL TUMOR; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADULT; AGED; CANCER STAGING; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; MALE; METASTASIS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDY; REFERENCE VALUE; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PEPTIDES, CYCLIC; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDIES; REFERENCE VALUES; SOMATOSTATIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0043132282     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.12.142     Document Type: Article

References (36)

1. Creutzfeldt W: Carcinoid tumors: Development of our knowledge. World J Surg 20:126-131, 1996
2. Wiedenmann B, John M, Ahnert-Hilger G, et al: Molecular and cell biological aspects of neuroendocrine tumors of the gastroenteropancreatic system. J Mol Med 76:637-647, 1998
3. Capella C, Heitz PU, Hofler H, et al: Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Digestion 55:1-23, 1994 (suppl 3)
4. Kvols LK, Moertel CG, O'Connell MJ, et al: Treatment of the malignant carcinoid syndrome: Evaluation of a long-acting somatostatin-analogue. N Engl J Med 315:663-666, 1986
5. Öberg K, Funa K, Alm G: Effects of leucocyte interferon on clinical symptoms and hormone levels in patients with midgut carcinoid tumors and carcinoid syndrome. N Engl J Med 309:129-133, 1983
6. Arnold R, Neuhaus C, Henning R, et al: Somatostatin-analogue sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors. World J Surg 17:511-519, 1993
7. Saltz L, Trochanowsky B, Buckley M, et al: Octreotide as an antineoplastic agent in the treatment of functional and non-functional neuroendocrine tumors. Cancer 72:244-248, 1993
8. Arnold R, Trautmann ME, Creutzfeldt W, et al: Somatostatin-analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumors. Gut 38:430-438, 1996
9. Faiss S, Räth U, Mansmann U, et al: Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion 60:469-476, 1999
10. Ducreux M, Ruszniewski P, Chayvialle JA, et al: The antitumoral effect of the long-acting somatostatin analogues lanreotide in neuroendocrine tumors. Am J Gastroenterol 95:3276-3281, 2000
11. Moertel CG, Lefkopoulo M, Lipsitz S, et al: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:563-565, 1992
12. Moertel CG, Kvols LK, O'Connell MJ, et al: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68:227-232, 1991
13. Lamberts SWJ, van der Lely AJ, de Herder WW, et al: Octreotide. N Engl J Med 334:246-254, 1996
14. Creutzfeld W, Bartsch HH, Jacubaschke K, et al: Treatment of gastrointestinal endocrine tumors with alpha-interferon and octreotide. Acta Oncol 30:529-535, 1991
15. Tiensuu Janson EM, Ahlström H, Andersson T, et al: Octreotide and interferon alfa: A new combination for the treatment of malignant carcinoid tumors. Eur J Cancer 28A:1647-1650, 1992
16. Joensun H, Kätkä K, Kujari H: Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide. Acta Endocrinol (Copenh.) 126:184-185, 1992
17. Nold R, Frank M, Kajdan U, et al: Kombinierte Behandlung metastasierter neuroendokriner Tumoren des Gastrointestinaltrakts mit Octreotid und Interferon alfa. Z Gastroenterol 32:193-197, 1994
18. Frank M, Klose KJ, Wied M, et al: Combination therapy with octreotide and alfa interferon: Effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 94:1381-1387, 1999
19. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organization, 1979, pp 22-27
20. Bender H, Maier A, Wiedenmann B, et al: Immunoluminometric assay of chromogranin A in serum with commercially available reagents. Clin Chem 38:2267-2272, 1992
21. Rubin DB, Schenker NS: Multiple imputation in health-care databases: An overview and some applications. Stat Med 10:585-598, 1991
22. Faiss S, Pape U, Riecken EO, et al: Prospective, randomized multicenter trial on the antiproliferative effect of lanreotide, interferon-alpha and the combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors. Proc Am Soc Clin Oncol 19:196, 2000 (abstr 1014)
23. Faiss S, Riecken EO, Wiedenmann B: Prospective, randomized multicenter trial on the antiproliferative effect of lanreotide, interferon-alpha and the combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors. Gastroenterology 118:218, 2000 (abstr 1006)
24. John M, Meyerhof W, Richter D, et al: Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut 38:33-39, 1996
25. Kubota A, Yamada Y, Kagimoto S, et al: Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 93:1321-1325, 1994
26. Buscail L, Saint-Laurent N, Chastre E, et al: Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 56:1823-1827, 1996
27. Taylor JE, Bogden AE, Moreau JP, et al: In vitro inhibition of human small cell lung carcinoma (NCL-H69) growth by somatostatin analogue. Biochem Biophys Res Commun 153:81-86, 1988
28. Siegel RA, Tolscavai L, Rudin M: Partial inhibition of the growth of transplanted Dunning rat prostate tumors with the long-acting somatostatin analogue Sandostatin (SMS 201-995). Cancer Res 48:4651-4655, 1988
29. Liebow CR, Reilly C, Serrano M, et al: Somatostatin analogues inhibit growth of pancreatic cancer stimulating tyrosine phosphatase. Proc Natl Acad Sci U S A 86:2003-2007, 1989
30. Bogden AE, Taylor JE, Moreau JP, et al: Response of human lung xenografts to treatment with a somatostatin analogue (somatuline). Cancer Res 50:4360-4365, 1990
31. Weckbecker G, Liu R, Tolcsvai L, et al: Antiproliferative effects of the somatostatin analogue octreotide (SMS 201.995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Res 52:4973-4978, 1992
32. Anthony L, Johnson D, Hande K, et al: Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol 32:217-223, 1993
33. Eriksson B, Renstrup J, Iman H, et al: High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: Clinical and biological effects. Ann Oncol 8:1041-1044, 1997
34. Detjen KM, Welzel M, Farwig K, et al: Molecular mechanism of interferon-alpha mediated growth inhibition in human neuroendocrine tumor cells. Gastroenterology 118:735-748, 2000
35. Öberg K: The action of interferon alpha on human carcinoid tumors. Semin Cancer Biol 3:35-41, 1992
36. Dirix LY, Vermeulen PB, Fierens H, et al: Long-term results of continuous treatment with recombinant interferon-alpha in patients with metastatic tumors: An antiangiogenic effect? Anticancer Drugs 7:175-181, 1996